Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

63.14 -3.26 (-4.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,068
Open 65.69
Bid (Size) 60.22 (1)
Ask (Size) 68.50 (2)
Prev. Close 66.40
Today's Range 62.62 - 69.72
52wk Range 21.10 - 79.02
Shares Outstanding 11,834,361
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Large Patient Population Is Key Driver For Bright Minds' Growth
BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025 
Via Benzinga
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data. 
Via Benzinga

Performance

YTD
+53.6%
+53.6%
1 Month
+39.0%
+39.0%
3 Month
+142.9%
+142.9%
6 Month
+90.7%
+90.7%
1 Year
+119.2%
+119.2%

More News

Read More
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
Biotechs on the Brink: 2 Stocks With Huge Potential
Via MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
Via The Motley Fool
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Via Benzinga
Topics Government
What's Going On With Bright Minds Biosciences Stock?
Via Benzinga
Topics Artificial Intelligence
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
MarketBeat Week in Review – 10/14 - 10/18
Via MarketBeat
Topics Artificial Intelligence Economy
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results
Via Benzinga
What's Going On With Bright Minds Biosciences Stock Friday?
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Via Benzinga
Topics Artificial Intelligence
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
Via AB Newswire
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
Via Benzinga
Topics Stocks
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
Via Benzinga
Bright Minds Biosciences Stock Surges Almost 1,500%
Via MarketBeat
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?
Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
What exchange does Bright Minds Biosciences Inc. - common stock trade on?
Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
What is the current price of Bright Minds Biosciences Inc. - common stock?
The current price of Bright Minds Biosciences Inc. - common stock is 63.14
When was Bright Minds Biosciences Inc. - common stock last traded?
The last trade of Bright Minds Biosciences Inc. - common stock was at 10/17/25 04:00 PM ET
What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
The market capitalization of Bright Minds Biosciences Inc. - common stock is 747.22M
How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
Bright Minds Biosciences Inc. - common stock has 747M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.